DK1797115T3 - Bakterielt atp-synthasebindingsdomæne. - Google Patents
Bakterielt atp-synthasebindingsdomæne. Download PDFInfo
- Publication number
- DK1797115T3 DK1797115T3 DK05794520.6T DK05794520T DK1797115T3 DK 1797115 T3 DK1797115 T3 DK 1797115T3 DK 05794520 T DK05794520 T DK 05794520T DK 1797115 T3 DK1797115 T3 DK 1797115T3
- Authority
- DK
- Denmark
- Prior art keywords
- atpe
- amino acids
- protein
- atpe protein
- dimensional structure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Claims (14)
1. Isoleret mutant atpE-protein, der omfatter en polypeptidsekvens valgt blandt SEQ ID NO: 01, der omfatter mindst én punktmutation placeret i en hvilken som helst af ATPase-bindingsstederne, der er placeret mellem aminosyrerne 14 til 34 eller mellem aminosyrerne 54 til 69, og SEQ ID NO: 03, der omfatter mindst én punktmutation placeret i en hvilken som helst af aminosyrerne 20 til 40 eller aminosyrerne 60 til 75, hvor proteinet inducerer resistens over for den antimikrobielle forbindelse DARQJ i figur 1.
2. Isoleret mutant atpE-protein ifølge krav 1, der omfatter en polypeptidsekvens valgt fra gruppen, der består af SEQ ID NO: 01, der omfatter mindst én punktmutation placeret i aminosyre 28 eller i aminosyre 63.
3. Isoleret mutant atpE-protein ifølge krav 1 eller 2, der er valgt blandt Mtb_R som vist i SEQ ID NO: 2, Msm_R0 9 som vist i SEQ ID NO: 4, Msm_R10 som vist i SEQ ID NO: 5.
4. Anvendelse af et polypeptid ifølge et hvilket som helst af kravene 1 til 3 i en fremgangsmåde til identificering af forbindelser, der interagerer med Fo-delen af en ATPase, og deres potentiale som antimikrobielle forbindelser.
5. Fremgangsmåde til evaluering af potentialet hos en testforbindelse for at interagere med et atpE-protein, hvilken fremgangsmåde omfatter; - molekylære modelleringsteknikker til frembringelse af den tredimensionelle struktur af et bindingssted ifølge et hvilket som helst af kravene 1 til 3; - anvendelse af et computerbaseret middel til udførelse af en tilpasningsoperation mellem testforbindelsen og den tredimensionelle struktur af bindingsstedet; og analyse af resultaterne af tilpasningsoperationen til kvantificering af forbindelsen mellem testforbindelsen og den tredimensionelle struktur af bindingsstedet.
6. Fremgangsmåde ifølge krav 5, hvor den tredimensionelle struktur frembringes ved hjælp af mindst aminosyrerne Ala24, Gly27, Phe53, Val57, Gly58, Glu61, Tyr64 og Phe65 i én C-subunit og aminosyrerne Ser182, Leu183, Leu185 og Arg186 i én A-subunit ved anvendelse af atomkoordinaterne ifølge en hvilken som helst af tabellerne 3, 4 eller 5 eller homologe strukturkoordinater, der omfatter en kvadratrod af middelkvadratafvigelsen for ikke-hydrogenatomer på mindre end ca. 1,5 Å.
7. Fremgangsmåde ifølge krav 5, hvor den tredimensionelle struktur frembringes ved anvendelse af atomkoordinaterne for aminosyrerne Ala21, Gly25 i A-kæden ifølge en hvilken som helst af tabellerne 3, 4 eller 5; aminosyrerne Ala24, Gly27, Phe53, Phe54, Val57, Gly58, Glu61, Tyr64, Phe65 i K-kæden ifølge en hvilken som helst af tabellerne 3, 4 eller 5; aminosyrerne Met17, Gly19 Gly20, Ala21, Ile22, Gly23, Ala24, Gly25, Ile26, Gly27, Asp28, Gly29, Ala31, Phe53, Thr56, Val57, Gly58, Leu59, Val60, Glu61, Ala62, Ala63/Pro63, Tyr64, Phe65 i L-kæden ifølge en hvilken som helst af tabellerne 3, 4 eller 5; og aminosyrerne Ser182, Leu183, Leu185 og Arg186 i M-kæden ifølge en hvilken som helst af tabellerne 3, 4 eller 5.
8. Isoleret nukleinsyresekvens, der koder for et isoleret mutant atpE-protein ifølge et hvilket som helst af kravene 1 til 3.
9. Vektor, der omfatter nukleinsyresekvensen ifølge krav 8.
10. Værtscelle, der bærer vektoren ifølge krav 9.
11. Fremgangsmåde til identificering af en antimikrobiel forbindelse, hvilken fremgangsmåde omfatter a) etablering af kontakt mellem celler, der udtrykker et atpE-protein, og en testforbindelse under fysiologiske betingelser og b) bestemmelse af, om testforbindelsen interagerer med atpE-proteinet, hvor atpE-proteinet er et mutant atpE-protein ifølge et hvilket som helst af kravene 1 til 3.
12. Fremgangsmåde til evaluering af potentialet hos en testforbindelse for at interagere med et mutant atpE-protein ifølge et hvilket som helst af kravene 1 til 3, hvilken fremgangsmåde omfatter; a) anvendelse af molekylære modelleringsteknikker til formulering af en tredimensionel struktur af det mutante atpE-protein ifølge et hvilket som helst af kravene 1 til 3; b) anvendelse af et computerbaseret middel til udførelse af en tilpasningsoperation mellem testforbindelsen og den tredimensionelle struktur af det mutante atpE-protein ifølge kravene 1 til 3; og c) analyse af resultaterne af tilpasningsoperationen til kvantificering af forbindelsen mellem testforbindelsen og den tredimensionelle struktur af det mutante atpE-protein ifølge kravene 1 til 3.
13. Fremgangsmåde ifølge krav 12, hvor den tredimensionelle struktur af atpE-proteinet frembringes ved anvendelse af atomkoordinaterne for Ile28, Glu51 og Ile63 fra E. coli (proteindatabase 1Q01) +/- en kvadratrod af middelkvadratafvigelsen for rygradsatomerne i aminosyrerne på højst 10 Å.
14. Fremgangsmåde ifølge krav 12, hvor den tredimensionelle struktur af atpE-proteinet frembringes ved anvendelse af atomkoordinaterne ifølge tabellerne 6 eller 7 +/- en kvadratrod af middelkvadratafvigelsen for rygradsatomerne i aminosyrerne på højst 1,5 Å.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04104720 | 2004-09-28 | ||
| US62050004P | 2004-10-20 | 2004-10-20 | |
| PCT/EP2005/054893 WO2006035051A1 (en) | 2004-09-28 | 2005-09-28 | A bacterial atp synthase binding domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1797115T3 true DK1797115T3 (da) | 2017-10-02 |
Family
ID=38965678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05794520.6T DK1797115T3 (da) | 2004-09-28 | 2005-09-28 | Bakterielt atp-synthasebindingsdomæne. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8088891B2 (da) |
| EP (1) | EP1797115B1 (da) |
| JP (2) | JP2008515395A (da) |
| KR (1) | KR101539021B1 (da) |
| CN (1) | CN101065397B (da) |
| AU (2) | AU2005288848A1 (da) |
| CA (1) | CA2579971C (da) |
| CY (1) | CY1119568T1 (da) |
| DK (1) | DK1797115T3 (da) |
| ES (1) | ES2636980T3 (da) |
| HK (1) | HK1114619A1 (da) |
| HR (1) | HRP20171388T1 (da) |
| HU (1) | HUE033609T2 (da) |
| IL (1) | IL182185A (da) |
| LT (1) | LT1797115T (da) |
| ME (1) | ME02935B (da) |
| NO (1) | NO342699B1 (da) |
| NZ (1) | NZ553693A (da) |
| PL (1) | PL1797115T3 (da) |
| PT (1) | PT1797115T (da) |
| RS (1) | RS56357B1 (da) |
| RU (1) | RU2418001C2 (da) |
| SI (1) | SI1797115T1 (da) |
| WO (1) | WO2006035051A1 (da) |
| ZA (1) | ZA200702540B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2440736A (en) * | 2006-08-10 | 2008-02-13 | Medical Res Council | Crystals of mutant p53 polypeptidtes |
| JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2685B1 (en) | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| EA038350B1 (ru) | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| US8454434B1 (en) * | 2012-06-15 | 2013-06-04 | Igt | Gaming system and method for providing an offer and acceptance game with progressive awards associated with a quantity of progressive tokens |
| JP5580383B2 (ja) | 2012-10-05 | 2014-08-27 | 株式会社 資生堂 | 美容機器及び通電方法及び記録媒体 |
| KR101522087B1 (ko) * | 2013-06-19 | 2015-05-28 | 삼성에스디에스 주식회사 | 미스매치를 고려한 염기 서열 정렬 시스템 및 방법 |
| CN110373399B (zh) * | 2019-07-09 | 2021-05-28 | 湖南省植物保护研究所 | 一种沼泽红假单胞菌Atps2蛋白及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993009103A1 (en) | 1991-11-01 | 1993-05-13 | The Upjohn Company | Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents |
| US6583266B1 (en) * | 1993-08-19 | 2003-06-24 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics |
| JP2004509069A (ja) * | 2000-05-19 | 2004-03-25 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐ−セレクチン、ｐ−およびｅ−セレクチン複合体の結晶構造、ならびにそれらの用途 |
| US20040101907A1 (en) * | 2000-09-19 | 2004-05-27 | Bussiere Dirksen E. | Characterization of the gsk-3beta protein and methods of use thereof |
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| EP1443937B1 (en) * | 2001-11-13 | 2008-06-18 | Ortho-McNeil Pharmaceuticals, Inc. | Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| PL222801B1 (pl) | 2002-07-25 | 2016-09-30 | Janssen Pharmaceutica Nv | Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je |
| AU2002951853A0 (en) * | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
-
2005
- 2005-09-28 DK DK05794520.6T patent/DK1797115T3/da active
- 2005-09-28 LT LTEP05794520.6T patent/LT1797115T/lt unknown
- 2005-09-28 EP EP05794520.6A patent/EP1797115B1/en active Active
- 2005-09-28 ME MEP-2017-214A patent/ME02935B/me unknown
- 2005-09-28 PL PL05794520T patent/PL1797115T3/pl unknown
- 2005-09-28 ES ES05794520.6T patent/ES2636980T3/es active Active
- 2005-09-28 KR KR1020077009488A patent/KR101539021B1/ko active IP Right Grant
- 2005-09-28 RS RS20170911A patent/RS56357B1/sr unknown
- 2005-09-28 NZ NZ553693A patent/NZ553693A/xx active Application Revival
- 2005-09-28 RU RU2007116144/10A patent/RU2418001C2/ru active
- 2005-09-28 US US11/576,023 patent/US8088891B2/en not_active Expired - Fee Related
- 2005-09-28 AU AU2005288848A patent/AU2005288848A1/en not_active Abandoned
- 2005-09-28 SI SI200532172T patent/SI1797115T1/sl unknown
- 2005-09-28 PT PT57945206T patent/PT1797115T/pt unknown
- 2005-09-28 CN CN200580040762.3A patent/CN101065397B/zh active Active
- 2005-09-28 JP JP2007532910A patent/JP2008515395A/ja not_active Withdrawn
- 2005-09-28 HU HUE05794520A patent/HUE033609T2/en unknown
- 2005-09-28 WO PCT/EP2005/054893 patent/WO2006035051A1/en active Application Filing
- 2005-09-28 CA CA2579971A patent/CA2579971C/en active Active
-
2007
- 2007-03-26 IL IL182185A patent/IL182185A/en active IP Right Grant
- 2007-03-27 ZA ZA200702540A patent/ZA200702540B/xx unknown
- 2007-04-30 NO NO20072237A patent/NO342699B1/no unknown
-
2008
- 2008-04-24 HK HK08104581.9A patent/HK1114619A1/zh not_active IP Right Cessation
-
2011
- 2011-11-29 US US13/306,255 patent/US8378085B2/en active Active
-
2012
- 2012-05-11 JP JP2012109892A patent/JP5837852B2/ja active Active
- 2012-08-16 AU AU2012216368A patent/AU2012216368B2/en not_active Ceased
-
2017
- 2017-09-14 HR HRP20171388TT patent/HRP20171388T1/hr unknown
- 2017-09-20 CY CY20171100997T patent/CY1119568T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8378085B2 (en) | Bacterial ATP synthase binding domain | |
| Segala et al. | New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure | |
| Woehlke et al. | Microtubule interaction site of the kinesin motor | |
| Bussiere et al. | The structure of VanX reveals a novel amino-dipeptidase involved in mediating transposon-based vancomycin resistance | |
| Davies et al. | Structural and thermodynamic comparison of the catalytic domain of AMSH and AMSH-LP: nearly identical fold but different stability | |
| Ashok et al. | Discovery of compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin | |
| JP2010529418A (ja) | Ｍｄｍ２とプロテアソームの間の結合の検出方法 | |
| Im et al. | The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design | |
| Junaid et al. | Insights into the mechanisms of the pyrazinamide resistance of three pyrazinamidase mutants N11K, P69T, and D126N | |
| Albesa-Jové et al. | The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053 | |
| Rahi et al. | Exploring the interaction between Mycobacterium tuberculosis enolase and human plasminogen using computational methods and experimental techniques | |
| Odiba et al. | A new variant of mutational and polymorphic signatures in the ERG11 gene of fluconazole-resistant candida albicans | |
| Pakamwong et al. | Identification of potent DNA gyrase inhibitors active against Mycobacterium tuberculosis | |
| Yokoyama et al. | Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance | |
| US20030229453A1 (en) | Crystals and structures of PAK4KD kinase PAK4KD | |
| Yang et al. | Crystal structure of 3-carboxy-cis, cis-muconate lactonizing enzyme from Pseudomonas putida, a fumarase class II type cycloisomerase: enzyme evolution in parallel pathways | |
| Shakibaie et al. | Insight into stereochemistry of a new IMP allelic variant (IMP-55) metallo-β-lactamase identified in a clinical strain of Acinetobacter baumannii | |
| US20080305041A1 (en) | Pf4 Pharmacophores and Their Uses | |
| Kandasamy et al. | Homology modelling, docking, pharmacophore and site directed mutagenesis analysis to identify the critical amino acid residue of PknI from Mycobacterium tuberculosis | |
| US20030187220A1 (en) | Crystals and structures of a flavin mononucleotide binding protein (FMNBP) | |
| US20030101005A1 (en) | Crystals and structures of perosamine synthase homologs | |
| Kamsri et al. | Bioisosteric design identifies inhibitors of Mycobacterium tuberculosis DNA Gyrase ATPase activity | |
| Tolufashe | Investigating the inhibition mechanism of L, D-transpeptidase 5 from Mycobacterium tuberculosis computational methods. | |
| Mokhawa | Using Bioinformatics tools to Screen for Trypanosomal Cathepsin B Cysteine Protease Inhibitors from the SANCDB as a Novel Therapeutic Modality against Human African Trypanosomiasis (HAT) | |
| JP2007522792A (ja) | ｃ−Ａｂ１チロシン・キナーゼ・ドメインの結晶及び構造 |